A research programme by the Access to Medicine Foundation
Publication - published on 24 Nov 2015

Access to hepatitis C medicine

The Bulletin of the World Health Organization has published the latest study from the Access to Medicine Foundation: on how the world’s largest pharma companies are improving access to hepatitis C treatment.

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV). There is a global epidemic of hepatitis C, with approximately 185 million people estimated to be infected in 2005 and 350 000–500 000 deaths estimated annually. Over 80% of those affected by the disease live in low- and middle income countries, especially in central, north and west Africa. Several middle-income countries such as Egypt, Nigeria and Pakistan have a high burden of hepatitis C. HCV is most often spread when infected blood enters the body. High-risk populations include intravenous drug-users and recipients of blood transfusions in poorly controlled environments; but the virus is also found in the general population. There are six genotypes of HCV, with distributions varying by region. It is possible for a person to be infected with multiple genotypes; 55–85% of people will develop chronic infection and about one third of these, if not treated, will eventually develop liver cirrhosis or hepatocellular carcinoma. Approximately 80% of newly-infected people are asymptomatic, which makes it difficult to diagnose and treat those who go on to develop chronic infection.


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.